THE
TRIPLE
THREAT
APPROACH TO WOUND CARE
Example of standard in vitro laboratory tests which demonstrate that coactiv+™ Antimicrobial Wound Gel eliminates biofilms of major wound pathogens.
Effective Wound Healing
In vitro laboratory data shows that coactiv+™ Antimicrobial Wound Gel disrupts the polymeric matrix enhancing the inactivation of biofilm embedded microorganisms, and aids in inhibiting metalloprotease activity while maintaining a moist wound environment conducive to wound healing.
“The best biomarker to predict that a wound will not heal is the presence of high levels of proteases.”
Gregory Schultz, Professor Emeritus of Obstetrics and Gynecology in the College of Medicine at the University of Florida, Past President of the Wound Healing Society, past member of the National Pressure Injury Advisory Panel, and Chief Scientific Officer for Kane Biotech Inc.
IN VITRO LABORATORY DATA SHOWS REDUCTION IN PROTEASE ACTIVITIES
Standard in vitro laboratory tests demonstrate that coactiv+™ effectively inhibits metalloproteases (matrix metalloprotease and TACE).
Critical Proteases That Can Impair Healing
Chronic wounds have a prolonged inflammatory phase which hinders the normal wound healing process. These wounds are often colonized by biofilm forming bacteria that can trigger the inflammatory process and elevate levels of matrix metalloproteases. These enzymes often cause tissue damage.
Ease of Use Thermo-Gelling System
What separates coactiv+™ Antimicrobial Wound Gel from its competitors is its unique patented coactiv+™ technology that includes a non-ionic pluronic surfactant that creates a thermo-reversible gelling system. At body temperature, it forms a thick gel that helps it to stay in place on the wound without any runoff.
At lower temperatures (such as below 60°F), the wound gel liquifies, allowing it to be easily applied and rinsed off making it ideal for sensitive wounds. For instance, on burns the gel can be applied cold, in its liquid form, allowing it to flow into every crevice of the wound while providing a soothing sensation to the patient. Once applied, it will rapidly return to its gel-like state when warmed to body temperature.
In addition, the non-greasy, fragrance-free gel is clear, which enables easy visualization of the wound bed.
Priced for Accessibility for All Patients
coactiv+™ Antimicrobial Wound Gel will be priced below current public reimbursement parameters under the surgical dressing policy (A-6248), U.S. $21.61/ounce with U.S. $64.83/3oz the monthly allowable. It is the only premium hydrogel priced for accessibility for all patients while providing the benefit of significant efficacy in a unique thermo-gelling application.
coactiv+™ Antimicrobial Wound Gel provides an affordable, effective, and innovative treatment option for more patients than ever before with chronic, acute, and surgical wounds as well as first- and second-degree burns.
“Our goal from the beginning was to develop a premium hydrogel that is accessible to all patients.”
Marc Edwards, President and Chief Executive Officer, Kane Biotech.